Gubra
GUBRA
Performance
About Gubra
Gubra is a peptide-focused biotech company that provides high-end preclinical contract research and peptide-based drug discovery services. It specializes in metabolic and fibrotic diseases, offering advanced models, imaging, and analytics to accelerate early-stage development. The company operates from Denmark (Headquarters in Hørsholm) with a presence in the United States (Boston) and collaborates with global partners to advance peptide therapeutics from discovery to development.
Recent News
Biotech in 2025: A Retrospective
Amylyx Pharmaceuticals Q1 Earnings Call Highlights
AbbVie, Gubra Post Obesity Data; Regeneron Obesity Drug Succeeds in China
10 Obesity Drug Companies to Watch in 2026
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
Recent Deals
No recent deals for this company.